RecruitingPhase 2NCT06804655

Pharmacoscopy for Patients With Refractory Primary Brain Tumors

Sponsor

University of Zurich

Enrollment

40 participants

Start Date

Sep 11, 2026

Study Type

INTERVENTIONAL

Conditions

Glioblastoma Meningioma Glioma Brain (Nervous System) Cancers Medulloblastoma Ependymoma Rare Primary Brain Tumors Rare CNS Primary Tumors

Summary

Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level. This personalized therapeutic approach was developed and validated in pre-clinical glioma models. With the current research proposal, we seek to establish feasibility for a clinical interventional trial for patients with refractory primary brain tumors that is based on pharmacoscopy-guided selection of treatment. The study is supported by an unrestricted grant from Anti Cancer Fund.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Pharmacoscopy 1.0 for people with brain (nervous system) cancers, ependymoma, and other related conditions. The study is currently recruiting participants at 3 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPharmacoscopy 1.0

The intervention is the submission of freshly obtained surgical material to ex vivo drug profiling which we term pharmacoscopy (PCY). The performance study is interventional as the test results shall influence patient management decisions and/or may be used to guide treatment.